Mark Alberts

Chief

UConn Health

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Mark Alberts is the Chief at Hartford HealthCare in the United States. His research focuses on ischemic stroke prevention, anticoagulant therapies, and the economic impact of stroke management. Recent articles by Professor Alberts demonstrate his commitment to advancing knowledge in the field of stroke care and treatment outcomes for patients with atrial fibrillation and other related conditions.

Articles (9)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (2)

Claire Shovlin

Imperial College London

UNITED KINGDOM

View details

Anthony Kim

Professor

UCSF

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Mark Alberts

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

In ischemic stroke prevention, apixaban and aspirin do not differ for intracranial hemorrhage events

In patients with subclinical AF, apixaban vs. aspirin reduced stroke or systemic embolism at 3.5 y in those with previous stroke or TIA

Health Care Resource Use and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Polypharmacy Patients With Obesity

Heterogeneity of State Stroke Center Certification and Designation Processes

Ischemic Stroke in Patients With Pulmonary Arteriovenous Fistulas

Outcomes Among Patients With Reversible Cerebral Vasoconstriction Syndrome: A Nationwide United States Analysis

Risk of Stroke Outcomes in Atrial Fibrillation Patients Treated with Rivaroxaban and Warfarin

Healthcare costs before and after stroke in patients with non-valvular atrial fibrillation who initiated treatment with rivaroxaban or warfarin

PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibition and Stroke Prevention

Collaborators (2)

Claire Shovlin

Anthony Kim

Make your next move.